MX2018006799A - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MX2018006799A MX2018006799A MX2018006799A MX2018006799A MX2018006799A MX 2018006799 A MX2018006799 A MX 2018006799A MX 2018006799 A MX2018006799 A MX 2018006799A MX 2018006799 A MX2018006799 A MX 2018006799A MX 2018006799 A MX2018006799 A MX 2018006799A
- Authority
- MX
- Mexico
- Prior art keywords
- mometasone
- formoterol
- solvates
- prodrugs
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe una composición farmacéutica. La composición comprende al menos un compuesto de mometasona seleccionado de mometasona, sales de mometasona farmacéuticamente aceptables, profármacos de mometasona, solvatos de mometasona, solvatos de sales de mometasona farmacéuticamente aceptables y solvatos de profármacos de mometasona y un componente propelente que comprende 1,1-difluoroetano (R-152a). En una forma de modalidad preferida, la composición también comprende al menos un compuesto de formoterol seleccionado de formoterol, sales de formoterol farmacéuticamente aceptables, profármacos de formoterol, solvatos de formoterol, solvatos de sales de formoterol farmacéuticamente aceptables y solvatos de profármacos de formoterol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1521462.0A GB2545025A (en) | 2015-12-04 | 2015-12-04 | Pharmaceutical composition |
PCT/GB2016/053804 WO2017093755A1 (en) | 2015-12-04 | 2016-12-02 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018006799A true MX2018006799A (es) | 2018-11-09 |
Family
ID=55234449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018006799A MX2018006799A (es) | 2015-12-04 | 2016-12-02 | Composicion farmaceutica. |
Country Status (10)
Country | Link |
---|---|
US (6) | US20180264007A1 (es) |
EP (3) | EP3383367B1 (es) |
JP (2) | JP6993335B2 (es) |
CN (2) | CN108289842B (es) |
AU (3) | AU2016364005B2 (es) |
CA (1) | CA3007046C (es) |
ES (1) | ES2796343T3 (es) |
GB (1) | GB2545025A (es) |
MX (1) | MX2018006799A (es) |
WO (1) | WO2017093755A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
GB2573297A (en) * | 2018-04-30 | 2019-11-06 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
WO2019236559A1 (en) * | 2018-06-04 | 2019-12-12 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
FR3107039B1 (fr) * | 2020-02-07 | 2022-03-18 | Aptar France Sas | Valve doseuse avec chambre de dosage améliorée |
EP4106722A1 (en) * | 2020-02-20 | 2022-12-28 | Chiesi Farmaceutici S.p.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE236617T1 (de) * | 1994-12-22 | 2003-04-15 | Astrazeneca Ab | Aerosol-arzneiformulierungen |
GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
AU2001278115A1 (en) * | 2000-08-04 | 2002-02-18 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
AR036358A1 (es) * | 2001-08-28 | 2004-09-01 | Schering Corp | Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma |
GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
EP2117504A1 (en) * | 2007-02-09 | 2009-11-18 | Schering Corporation | Stable pharmaceutical drug aerosols |
EP2222272B1 (en) * | 2008-08-07 | 2012-11-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US8236786B2 (en) * | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US20120252824A1 (en) * | 2009-06-16 | 2012-10-04 | John Brew | Drug Combinations and Uses in Treating a Coughing Condition |
US20120238559A1 (en) * | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
UA113832C2 (xx) * | 2009-12-23 | 2017-03-27 | Комбінаційна терапія для хозл | |
CN102416179B (zh) * | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
CN111150728B (zh) * | 2013-12-30 | 2024-02-06 | 奇斯药制品公司 | 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物 |
GB2545025A (en) | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
EP3701940A1 (en) * | 2015-12-04 | 2020-09-02 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
AU2017328910B2 (en) * | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
-
2015
- 2015-12-04 GB GB1521462.0A patent/GB2545025A/en not_active Withdrawn
-
2016
- 2016-12-02 EP EP16823027.4A patent/EP3383367B1/en active Active
- 2016-12-02 CA CA3007046A patent/CA3007046C/en active Active
- 2016-12-02 EP EP19178815.7A patent/EP3563831A1/en not_active Withdrawn
- 2016-12-02 JP JP2018529067A patent/JP6993335B2/ja active Active
- 2016-12-02 US US15/781,060 patent/US20180264007A1/en not_active Abandoned
- 2016-12-02 CN CN201680071093.4A patent/CN108289842B/zh active Active
- 2016-12-02 WO PCT/GB2016/053804 patent/WO2017093755A1/en active Application Filing
- 2016-12-02 MX MX2018006799A patent/MX2018006799A/es active IP Right Grant
- 2016-12-02 EP EP19178833.0A patent/EP3563832A1/en active Pending
- 2016-12-02 ES ES16823027T patent/ES2796343T3/es active Active
- 2016-12-02 CN CN202111072725.8A patent/CN113908164A/zh active Pending
- 2016-12-02 AU AU2016364005A patent/AU2016364005B2/en active Active
-
2019
- 2019-03-05 AU AU2019201521A patent/AU2019201521B2/en active Active
- 2019-03-05 AU AU2019201520A patent/AU2019201520C1/en active Active
- 2019-09-09 US US16/565,217 patent/US20200000826A1/en not_active Abandoned
- 2019-09-09 US US16/565,226 patent/US20190388438A1/en not_active Abandoned
- 2019-12-23 JP JP2019231998A patent/JP6993398B2/ja active Active
-
2022
- 2022-09-14 US US17/944,666 patent/US20230029174A1/en active Pending
- 2022-09-14 US US17/944,637 patent/US20230029180A1/en active Pending
- 2022-10-19 US US17/969,250 patent/US20230051849A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020073514A (ja) | 2020-05-14 |
GB2545025A (en) | 2017-06-07 |
CA3007046C (en) | 2021-05-11 |
US20180264007A1 (en) | 2018-09-20 |
BR112018011269A2 (pt) | 2018-11-21 |
AU2019201521A1 (en) | 2019-03-28 |
GB201521462D0 (en) | 2016-01-20 |
AU2019201520A1 (en) | 2019-03-28 |
ES2796343T3 (es) | 2020-11-26 |
CN108289842A (zh) | 2018-07-17 |
AU2016364005A1 (en) | 2018-06-21 |
US20230051849A1 (en) | 2023-02-16 |
JP6993398B2 (ja) | 2022-01-13 |
CA3007046A1 (en) | 2017-06-08 |
JP2019503997A (ja) | 2019-02-14 |
US20230029174A1 (en) | 2023-01-26 |
CN108289842B (zh) | 2021-10-22 |
US20190388438A1 (en) | 2019-12-26 |
EP3563832A1 (en) | 2019-11-06 |
AU2019201520C1 (en) | 2020-12-10 |
EP3383367A1 (en) | 2018-10-10 |
AU2016364005B2 (en) | 2019-09-26 |
CN113908164A (zh) | 2022-01-11 |
AU2019201521B2 (en) | 2020-07-16 |
AU2019201520B2 (en) | 2020-07-09 |
EP3383367B1 (en) | 2020-03-25 |
US20200000826A1 (en) | 2020-01-02 |
US20230029180A1 (en) | 2023-01-26 |
JP6993335B2 (ja) | 2022-01-13 |
EP3563831A1 (en) | 2019-11-06 |
WO2017093755A1 (en) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018006800A (es) | Composicion farmaceutica. | |
EP3778608A4 (en) | POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USES | |
PH12019500579A1 (en) | Pharmaceutical composition | |
MX2018006799A (es) | Composicion farmaceutica. | |
SG11202104687SA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
IL276169A (en) | Peptide YY pharmacological formulations, compositions and methods | |
SG11202011886TA (en) | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF | |
MX2019003099A (es) | Composicion farmaceutica. | |
IL283539A (en) | 3,3-difluoroallylamines or their salts and pharmaceutical preparations containing them | |
SG11202104686QA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
MX2019003097A (es) | Composicion farmaceutica. | |
EP3773900A4 (en) | HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
MX2021010022A (es) | Composicion farmaceutica. | |
EP3539978A4 (en) | NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT | |
EP3750537A4 (en) | PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION | |
NZ733451A (en) | Combination therapy for pulmonary hypertension | |
PH12017502148A1 (en) | Pharmaceutical compositions and use thereof | |
IL279877A (en) | Ibusidanib forms and pharmaceutical preparations | |
MX2018014790A (es) | Formulacion combinada de tres compuestos antivirales. | |
IL284132A (en) | A pharmaceutical compound, a method for its preparation and its use as a medicinal substance | |
ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof | |
EP3845528A4 (en) | PYRAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
MX2019008847A (es) | Profarmacos de cisteamina. | |
TN2016000561A1 (en) | Stabilized desmopressin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |